

Health and Medical Research Fund Investigator-initiated Projects

Explanatory Notes on Grant Application

IMPORTANT!

- All Principal Applicants (PAs) **MUST** read this document in conjunction with the *Guidance Notes on Grant Application (the Guidance Notes)* before completing the electronic Application Form (e-Form).
- Applications that are incomplete, inconsistent with the submission requirements, out-of-scope or insufficiently detailed to peer review will not be processed and may result in administrative withdrawal. Applications which do not use the standard proposal template for Research and Health Promotion Project respectively (Section 10 of e-Form) will be treated as incomplete.
- For general enquiries about completing the e-Form, please contact the Research Fund Secretariat (the Secretariat) (email: rfs@healthbureau.gov.hk).

GENERAL INFORMATION

1. All applications must be submitted via the electronic Grant Management System (eGMS) (<https://rfs.healthbureau.gov.hk/eGMS/>) by completing the e-Form on or before the deadline of submission specified by the Secretariat. PAs who are unfamiliar with the eGMS are strongly advised to prepare their applications **well before the deadline of submission** to avoid unexpected situations. PA will receive an acknowledgement email from the eGMS after successful submission of his/her application by Administering Institution (AI) to the Secretariat.
2. The *Quick Guide for completing the e-Form* is available at **Annex A**.

GRANT APPLICATION FORM

Area of Project: Indicate the area of research (public health, human health and health services or prevention, treatment and control of infectious diseases or advanced medical research or health promotion) and the type of research (clinical or clinical study (Chinese medicine) or basic/pre-clinical where required) in the appropriate boxes.

- As HMRF emphasises the importance of translational potential of research findings, only **clinical research and research on infectious diseases with public health implications** will be supported. Making reference to the definition of clinical research by the National Institutes of Health of the United States¹, clinical research refers to “research with human subjects that is:

¹ National Institutes of Health of the United States <https://grants.nih.gov/policy/clinical-trials/glossary-ct.htm>

- (a) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator directly interacts with human subjects. It includes: (i) mechanisms of human disease, (ii), therapeutic interventions, (iii) clinical trials, or (iv) development of new technologies. Excluded from this definition are in vitro studies that utilise human tissues that cannot be linked to a living individual;
- (b) Epidemiological and behavioural studies; and
- (c) Outcomes research and health services research”
- **Research proposals on infectious diseases** should focus on those diseases which are prevalent in or pose threat to Hong Kong and neighbouring regions or areas in which the Hong Kong academic community has a competitive edge. Research proposals on infectious diseases with public health implications from bench to bedside and at community level, and with translational value are supported.
- **Chinese medicine research** must be clinical research which is based on Chinese medicine theory or clinical research on Chinese medicine theory and methodology.

Please refer to paragraph 1.2 of the *Guidance Notes* for details.

1. **Submission:** If this is a resubmission, please quote the previous reference number, select the rating of the previous submission (refer to paragraph 2.4.3 of the *Guidance Notes*, only those rated “2” or above are eligible for resubmission), and attach a structured point-by-point response to the Grant Review Board (GRB) Assessment Report (GRB and reviewers’ comments using standard template) in PDF file. **The limit of the file size is 800KB.**
2. **Funding Request:** Please select the appropriate category according to the proposed grant amount. For application of seed grant (i.e. grant ceiling is HK\$500,000 or below), please refer to paragraph 2.1.2 of the *Guidance Notes*.
3. **Thematic Priorities:** Please select the respective reference code of the **most relevant** thematic priority. If the application is outside the thematic priorities, please select “N/A” (i.e. Not Applicable). Please refer to the [Secretariat’s website](#) for details and reference codes of the thematic priorities.
4. **Project Title:** The project title should be concise but informative and self-explanatory. **Limit to 25 words.**
5. **Abstract of Project:** Presented in **BMJ house style** of **not more than 250 words** with the following headings: objectives; hypothesis to be tested; design and subjects; study instruments;

interventions; main outcome measures; data analysis and expected results. For details, please refer to <http://www.bmj.com/about-bmj/resources-authors/house-style>.

6. **Potential Application of Research Findings:**

Please explain how the research findings will benefit patients and/or the healthcare system. Describe in simple language the potential of the research findings to improve patient care, population health, influence clinical practice and/or health services management, or inform health policy in Hong Kong and elsewhere. What are the potential facilitators and barriers to this impact being achieved? Elaborate in **not more than 500 words**.

7. **Applicants (Project Team):** Each application should have one PA and not more than nine co-applicants (Co-As). The email address of each applicant must be entered twice to minimise incorrect entries. **The PA's email address entered in the e-Form will be used by the Secretariat for all communication relating to the application, including announcement of result.** The employment relationship between the PA and the AI should be made clear. The PA shall be **based in a Hong Kong organisation** throughout the project period and be employed by the AI at the time of submitting the application. If an applicant holds more than one post, e.g., one in University and one in Hospital or another Service or Unit, details of the position at the AI should be stated. The ORCID ID is optional. All applicants are expected to be personally and actively engaged in the project. Each applicant must provide his/her personal particulars and their specific roles and responsibilities on this project.

8. **Proposed Field:** Please select at least one group and field. The full list is at **Annex B**.

9. **Keywords:** Please enter up to 10 keywords for the project.

10. **Project Proposal:**

To ensure consistency and fairness, applicants must strictly comply with the formatting requirements listed below. The Secretariat **will not process applications that do not comply with these formatting requirements and/or wrong proposal template has been used**. In particular, insufficiently detailed proposals may be withdrawn.

The proposal templates for Sections 10(a) – (h) can be downloaded from the [Secretariat's website](#). Depending on the type of proposal submitted, please follow the relevant guidelines as follows –

Format (Applies to both research projects and health promotion projects)

Word limit: **Sections 10(a) – (d) inclusive: Not more than 4,000 words.** Please provide the word count for Sections 10(a) – (d). Proposal beyond the word limit will NOT be considered. Figures and tables must be

appended separately and SHOULD NOT be embedded within the text.

- Margin: Left at least 2.5cm. Others at least 1.5cm.
Font: At least 10-point. Preferably Arial.
Character spacing: Normal
Line spacing: At least Single.

Proposed Research Project

Area of Project –

- **Public health, human health and health services**
- **Infectious diseases**
- **Advanced medical research**

Proposal template Sections 10(a) – (h) of the proposal, with the standard header “**2023 HMRF Open Call – Research Proposal**”, should be **attached as a PDF file and the maximum file size (600KB)** to the e-Form.

Content

- a. **Title:** Same as Section 4
- b(i). **Research in Context:** Answer the two questions:
- (i) What is the existing evidence before this study based on an up-to-date literature search? State clearly whether research on a similar topic has been / is being carried out. Outline the research approaches in other studies and highlight their deficiencies and the research gap.
 - (ii) How will this study add value to existing evidence to improve patient care, population health, influence clinical practice and/or health services management, or inform health policy in Hong Kong and elsewhere?
- b(ii). **Introduction:** Explain the relevance of the proposal to the scope of the fund. Elaborate in details with references to support the answers provided to b(i) above.
- c. **Aims and Hypotheses to be Tested:** State the aims and hypotheses, wherever possible, as a list of questions to which answers will be sought.
- d. **Plan of Investigation:** Give practical details of how answers will be obtained to the questions posed.

For advanced medical research, please state clearly how the clinical studies apply advanced technologies to facilitate the translation of knowledge generated from health and health services or infectious diseases studies into clinical practice and to inform health policies.

For research project addressing the thematic priority of Implementation Science, please state clearly the proposed framework(s)/model(s) to analyse barriers and facilitators of implementation outcomes.

For seed grant application (i.e. grant ceiling is HK\$500,000), please state clearly the pre-defined outcome indicators that would enable scale-up to a larger project and/or enhance

the efficacy/effectiveness of existing practice.

Essential information should include –

- (i) **Study design** described in sufficient detail to allow assessment of workload and timetable and including but not limited to, experiments, observations to be made, randomisation method where relevant, and the use of controls.
 - (ii) **Methods** to be employed, giving references where these are non-standard. Where new methods are being developed, arrangements for establishing validity and reliability should be described. Examples of non-standard questionnaires, tests etc. should accompany the application or their content be clearly indicated.
 - (iii) **Subjects** to be included in the study. Justification for sample size and power analysis to support the chosen sample size must be provided.
 - (iv) **Data processing and analysis** including outcome measures, means of validating records, and the type of statistical analysis to be carried out.
 - (v) **Potential pitfalls and contingency plans** describing potential problem(s) that may be encountered during implementation of the study and providing a proactive strategy to continue the project if such problems are encountered.
- e. **Existing Facilities:** Describe resources and facilities available for supervision, equipment, space, staffing, relevant departmental interests, and collaboration. Supplementary sponsorship must be fully justified. Applicants shall state clearly whether any supplementary support has been/will be received from other sources, including but not limited to monetary, investigational new drugs/devices, reagents, and consumables and rental of equipment.
- f. **Justification of Requirements:** The staff requirement should be justified in terms of expertise and workload required by the research. Reasons should be given for selecting particular types of equipment, for purchasing of services and provision of incentives, etc. Please refer to the allowable and unallowable items at **Appendix B** of the *Guidance Notes*.
- g. **Plan to Disseminate Research Findings to End Users:** Describe the ways in which the research results will be disseminated.
- h. **Key References:** Include a maximum of 40 references in Vancouver style. Follow the “*Uniform Requirements for Manuscripts Submitted to Biomedical Journals*” at www.icmje.org/index.html for referencing. If it is considered essential to cite work by the applicants that are *in press* for publication, please provide a copy (PDF file) in “Section 10(j) – List of additional materials”.

Proposed Health Promotion Project

Area of Project - Health promotion

Proposal template Sections 10(a) – (h) of the proposal, with the standard header “**2023 HMRF Open Call – Health Promotion Proposal**”, should be **attached as a PDF file and the maximum file size (600KB)** to the e-Form.

Content

- a. **Title:** Same as Section 4
- b. **Justification for Conducting the Project:** Explain the health needs of the local community (supported by published data or relevant experiences). Provide existing evidence based on an up-to-date literature search. State whether project on a similar topic has been / is being carried out, outline the approaches in other projects and highlight their deficiencies and the gap in health promotion, and explain how will this project add value to existing evidence in addressing the health needs of the local community. Key references should be cited.
- c. **Aim and Objectives:** State the aims, and a list of objectives that are specific, measurable, achievable, relevant, and time-bound.
- d. **Project Plan:** Give practical details of how the stated objectives will be achieved. This should include information on –
State clearly the pre-set criteria for process and outcome evaluation based on the RE-AIM framework. Please refer to <https://re-aim.org/> for reference). **Failing to do so will lead to the application being incomplete for further processing.**

For project addressing the thematic priority of Implementation Science, please state clearly the proposed framework(s)/model(s) to analyse barriers and facilitators of implementation outcomes. Please refer to <https://www.fic.nih.gov/About/center-global-health-studies/neuroscience-implementation-toolkit/Pages/methodologies-frameworks.aspx> for reference.

For seed grant application (i.e. grant ceiling is HK\$500,000), please state clearly the pre-defined outcome indicators that would enable scale-up to a larger project and/or enhance the efficacy/effectiveness of existing practice.

- (i) **Target group** to be included in the project. Justify and explain the feasibility in reaching the target group size.
- (ii) **Implementation plan** described in sufficient detail to allow assessment of workload and timetable.
- (iii) **Contingency/alternative plan** if any problem encountered during implementation.
- (iv) **Cross-sector collaboration** including collaborations among public and private sectors, NGOs and tertiary institutions. Collaborations between NGOs and tertiary

institutions in project addressing the thematic priority of Implementation Science are highly encouraged.

- (v) **Indicators and targets** linked to the stated objectives, which can show to what extent are the objectives achieved according to the pre-set criteria for process and outcome evaluation based on RE-AIM framework.
 - (vi) **Evaluation plan** of how and when the indicators and targets will be measured throughout the project period to evaluate to what extent are the objectives achieved, including but not limited to pre- and post-intervention measurements according to the 5 key RE-AIM outcomes: Reach, Effectiveness (or Efficacy), Adoption, Implementation, and Maintenance.
 - (vii) **Results analysis** including how the evaluation results will be processed and interpreted to evaluate to what extent are the objectives achieved, including the type of statistical analysis to be carried out.
- e. **Existing Facilities:** Describe resources and facilities available for supervision, equipment, space, staffing, relevant departmental interests, and collaboration.
 - f. **Justification of Resource Requirements:** The staff requirement should be justified in terms of expertise and workload required by the project. If any income will be generated from the project, please specify how it will be used to offset the project expenditure. If any supplementary support, monetary or non-monetary, has been/will be received from other sources, including but not limited to devices, consumables and rental of equipment, please specify how it will meet the expenditure or resource requirement of the project. Please refer to the allowable and unallowable items at **Appendix B** of the *Guidance Notes*.
 - g. **Community Impact and Sustainability:** Describe how this project will enhance your community's capacity to promote health in the long run, such as establishment of partnership, transfer of knowledge, enhancement of problem solving abilities, or development of infrastructure. Describe the ways in which the project benefits will be disseminated and sustained after the funding period, such as alternative financial support, adoption of the project by AI or other organisation(s), establishment of new policies/procedures, or development of new products.
 - h. **Key References:** Include a maximum of 40 references in Vancouver style. Follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" at <http://www.icmje.org/index.html> for referencing. If it is considered essential to cite work by the applicants that are *in press* for publication, please provide a copy (PDF file) in "Section 10(j) – List of additional materials".

Sections 10(i) – (j) apply to both research projects and health promotion projects–

- i. **Attachment(s) referred in the proposal:** Include figures/tables, diagrams, questionnaires, tools, patient consent forms, etc. Figures and tables should be of sufficient size and resolution to allow easy reading. Use colour where applicable. List the items that

have been attached. Attach **not more than 5 files** (with total file size of 8 MB) properly titled in **PDF format** under this section.

- j. **List of additional materials:** Include ethics/safety approval(s), consent for accessing third-party data, letters of collaboration from study partners, quotation of budget item(s), supporting documents of training proposal, etc. List the items that have been attached. Attach **not more than 5 files** (with total file size of 5 MB) properly titled in **PDF format** under this section.

11. **Proposed Start and End Dates:** The expected start date is counted as the date on which the AI first incurs a direct cost for the funded project. The completion date should be entered based on the proposed duration of the grant. The grant period is calculated from the month closest to the start date up to the month including the end date of the project. The project start date must be after the announcement of funding decision. For example, applications submitted by the closing date of 28 March 2024 should not be expected to start before 1 December 2024.

12. **Timetable of Work:** In the table provided, describe clearly the key milestones of the project, the date (i.e. months after project commencement) by which these key milestones are expected to be reached, and the resulting deliverables. An example is included in the e-Form for reference, which may be overwritten/deleted in the final submission. Include 3-5 key milestones. These milestones will be used to determine the frequency of reporting progress to the Secretariat.

13. **Summary of Financial Support Requested:** The PA is not required to complete Section 13; the e-Form will automatically summarise the funding requested in Section 14. Costs should be rounded to the nearest dollar. PAs should refer to *Items Allowable and Unallowable for Reimbursement* and *Financial Arrangements* at **Appendices B and C** of the *Guidance Notes* respectively.

14. **Details of Financial Support Requested:** All items must be fully justified as stated in **Appendix B** of the *Guidance Notes*. Costs of work incurred ***before*** the commencement date or the writing-up of such work are ***not allowed***. Research work (e.g. subject recruitment) conducted before the commencement date which includes the period before and after application submission is not allowed. If such case is declared upfront before the Agreement is signed for fundable application, the PA has to adjust the funding scope and the funding amount for the GRB's consideration and approval.

Application should be based on ***actual prices***. Standard rates, if available, should be specified. No allowance should be made for inflation. Costs should be rounded to the nearest dollar.

The AI shall be responsible for the provision of the basic facilities required to support the project including employment service of the required project staff, procurement of services and equipment, accounting services, etc.

14a. Staff Details

The proposed project staff shall enter into **contract of employment** with the AI. Staff costs should be justified in terms of the level of expertise and workload required by the project. ***PAs should consult their finance office about the pay scale and the appropriate pay point proposed.***

In general, salary scales that apply to equivalent workers employed by the AI are acceptable. Funding may be requested for full-time (which may be for periods shorter than the duration of the grant) or part-time posts. For part-time staff, the effort on the project must be at least 20%. Monthly contributions to the Mandatory Provident Fund should also be included and absorbed in the monthly salary instead of a standalone item. Staff benefits such as gratuity, bonus, severance payment, untaken leave of staff employed and medical insurance costs will not be supported.

Information in this section should reflect salary costs for the ***entire*** project, based on the proposed salaries as at the date of the application and the estimated percentage on level of participation in the project. The ***actual*** costs for each financial year of the grant should be entered in “Staff Costs”.

Remarks for Sections 14(b) - (d): If the grant period exceeds 24 months and the expenses will be incurred for more than three financial years, the annual cost of the third financial year and thereafter should be grouped together.

14b. Staff Costs

Please provide an annual cost for each post identified in “Staff Details” above during the proposed project period.

14c. Other Expenses

Other expenses include consumable or equipment items costing less than HK\$10,000, conference (i.e. travel and subsistence), publication costs, reference materials, Audit fee, etc. Only direct costs can be charged to the project grant. Unit cost should be provided as far as possible, e.g. incentive per participant, whole genome sequencing cost per sample. Indirect costs of the project will not be considered.

For incentives

The purchase of gifts, coupons, etc., as incentives/tokens of appreciation for study participants is allowed if well justified with valid reason(s). A governance system shall be in place to adequately monitor the disbursement of incentives to ensure accountability and traceability.

For purchase of services

Purchase of services from non-local organisations, such as consultancy for project, experimental

work, Biosafety Level 3 (BSL-3)/P3 laboratory facilities, etc., is allowed if well justified with valid reason(s), which should include full justifications for not acquiring the resources/facilities in Hong Kong.

For travel and subsistence

The cost of local travel for project staff to attend clinics and training sites, for purposes directly related to the project are allowed.

14d. Equipment

Only include items dedicated to the project and costing HK\$10,000 or above. Items costing less than HK\$10,000 should be included under “Other Expenses”.

Purchase of particular types of equipment should be well justified by, providing details (including but not limited to, the needs of the project and cost, performance and specifications of the equipment) under section f of Section 10. Tendering should be carried out according to the AI’s procedures. The AI should pay attention to the transparency and fairness in the procurement process and follow its disposal procedures properly. Where the relevant guidelines are not in place, the institution should adopt the *Notes on Acquisition and Disposal of Equipment Items for Institutions without Established Guidelines*, which can be obtained from the Secretariat by email (rfs@healthbureau.gov.hk).

For computer equipment and software

The PA should provide valid justifications for purchase of software and computing equipment/facilities. Local departmental computing charges which can be assigned to the project will be considered as an allowable cost, including stationery supplies and software licences. Expenses for computing equipment specific for the project, such as notebook computers, software, etc., will be covered. Central computing facilities remain the responsibility of the AI. The purpose of any special software to be developed, e.g. commissioned in house, or modifications of existing software should be detailed and the development time required given in hours or man-months.

If external resources are to be used, the estimated time required, a breakdown of the resources required, and the cost per unit of computing time/purchase of consultancy should be given.

Any computing consumable to be purchased should be itemised under “Other Expenses” with a breakdown of both quantity and price.

Should computing advice be sought, details of the persons/organisations to be consulted should be given.

15. **Research Ethics/Safety Approval/Consent for Accessing Third-party Data:** The primary responsibility for seeking the relevant approval rests with the PA. Select the appropriate button to confirm if approvals for the respective research ethics, safety issues and/or consent for accessing

third-party data is required, is being sought or has been obtained from the proper authorities. Provision of regulatory/ethics approval(s)/consent is not required at the time of submission. PAs shall submit such approvals and/ or consent ***within 12 weeks*** (or as specified by the Secretariat) from the date of decision letter for the application, and should ensure that the regulatory/ethics approval(s)/evidence for accessing third-party data bear(s) the same project title as that in his/her approved application. The protocol/scope included in such approval(s)/ evidence for accessing third-party data must be the same as that in the application.

If PA is unable to provide such documentary evidence or information by the deadline stated, or the information is found to be incomplete or inaccurate, the processing of the application may be delayed or the application may be rejected. Letters of exemption for non-applicable regulatory committees are not required. For details regarding Independent Ethics Committee/Institutional Review Board (IEC/IRB), please refer to Section 3 of the following document published by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use at <https://www.ich.org/page/efficacy-guidelines>.

16. **Curriculum Vitae of All Applicants:** Each applicant listed in Section 7 must provide his/her personal particulars. The ORCID ID is optional. Up to five most recent relevant publications (including those submitted or in press) of applicant(s), and description of relevant experience should be listed.

17. **Similar or Related Proposals:**

Failure to make declaration may lead to application not eligible for further processing and shall be subject to penalty. Please refer to the *Management of Track Records of Applicants* which is available on the [Secretariat's website](#).

17a(i). PA and Co-A(s) listed in Section 7 **must indicate** whether they have submitted the current or similar application(s) (funded or rejected) to the HMRF or other funding agencies (local or overseas) **in the past three years from the closing deadline**. The following information should be uploaded to the e-Form: (i) a copy of each previously submitted similar application [*in PDF format and maximum file size (1MB)*]; and (ii) all comments raised by the funding agency **and** point-by-point responses to address these comments (if any) [*in PDF format and maximum file size (600KB)*].

17a(ii). PA and Co-A(s) listed in Section 7 **must indicate** whether they intend to submit the current or similar application(s) to the HMRF or other funding agencies (local or overseas) **in the next six months from the closing deadline**. The details of the similar application(s) and the similarities and differences between the current application and the similar application(s) should be provided.

At any time before the announcement of the funding decision of the current application, applicants are required to notify the Secretariat immediately by email to rfs@healthbureau.gov.hk about: (a) any other similar application(s) submitted to other funding agencies (local or overseas) in addition to those listed in the e-Form; (b) the funding decision of any similar application(s) once available, or (c) change in funding status, e.g. project is withdrawn or terminated.

18. **Other Applications and Track Record:**

18a(i). PA **must indicate** whether he/she has been awarded grant(s) currently ongoing or completed from the HMRF or other funding agencies (local or overseas) **in the past three years from the closing deadline**. PA should provide details of the funded project(s) undertaken by him/her in PA/Co-A(s) capacity, the similarities and differences between the current application and the funded project(s), and publications/scientific papers directly resulting from the funded project(s) as well as check the box if the project is funded by the HMRF.

18a(ii). All Co-A(s) listed in Section 7 **must indicate** whether they have been awarded grant(s) currently ongoing or completed from the HMRF or other funding agencies (local or overseas) **in the past three years from the closing deadline**. They should provide details of the funded project(s) undertaken by them in PA's capacity, the similarities and differences between the current application and the funded project(s) and publications/scientific papers directly resulting from the funded project(s) as well as check the box if the project is funded by the HMRF.

19. **Nomination of Reviewers**

19a. The PA can nominate up to **three non-local reviewers** whom they consider qualified to review this application. Nominated reviewers must be expert in the specialised fields and have experience in grant review. However, the final selection of non-local reviewers for any grant application is at the discretion of the Secretariat.

19b. When nominating non-local reviewers, the PA is responsible for the proper and complete declaration of any past or present significant personal and/or professional relationship between any of the applicant(s) listed in Section 7 and the nominated reviewer(s). Significant relationship includes, but is not limited to, spouse/partner/direct relative; close personal contact; employer/employee/business partner; mentor/student; departmental colleague; research collaborator, etc. **Failure to declare potential conflict of interest shall be subject to penalty.** Please refer to the *Management of Track Records of Applicants* which is available on the [Secretariat's website](#).

20. **Declaration and Authorisation**

The e-Form must be signed by all applicants, the Head of Department (or Head of Agency in NGO), and authorised persons on behalf of the AI and finance office via the eGMS.

To the best of knowledge of PA, the AI and any of the applicants listed in Section 7 or any of the proposed personnel and sub-contractors/agencies to be engaged in the project, PA should declare any actual or perceived conflict of interest, such as receiving any funding or assistance directly or indirectly from industries (including but not limited to tobacco related businesses, infant formula companies, or organisations funded by such businesses), or using the grant monies (budgeted under Sections 13 and 14) to purchase products or services from businesses owned wholly or partly by the AI or any of the applicants listed in Section 7, or any of the proposed personnel and sub-contractors/agencies to be engaged in the project.

Signature of Co-As: The research proposal must be endorsed by all Co-As. If Co-A(s) is/ are not an existing eGMS user, please register a Co-A's account from eGMS login page. If the PA has attached Co-A(s)' physical signature(s) (an email confirmation from Co-A(s) is acceptable), the relevant electronic signature is not required (i.e. the eGMS will not send out notification email to the Co-A(s) concerned for signing). The limit of the file size is 1MB.

The PA should make sure that all Co-As endorse the application as the track record for the whole project team might be adversely affected if misconduct/fraud is found. All project team members should be well aware of their participation and roles and responsibilities in the project. Please refer to the *Management of Track Records of Applicants* which is available on the [Secretariat's website](#).

AI: The e-Form must be endorsed by the Head of Department (or Head of Agency in NGO), and authorised persons on behalf of the AI and finance office. The email address of the Head of Department (or Head of Agency in NGO) must be entered twice to minimise incorrect entries.

Quick Guide for Completing the Electronic Application Form

(A) Minimum system requirements

To use the electronic Grant Management System (eGMS), your computer should meet these minimum system requirements -

1. Google Chrome¹ or Mozilla Firefox² or Safari 7+
2. Enable Transport Layer Security (TLS) version 1.2 in the browser
3. 1280 x 1024 Minimum Screen Resolution
4. Microsoft Office Word 2007 or above (for opening MS Word Offline Template)

¹ Recommended version for Google Chrome is 57 or above.

² Recommended version for Mozilla Firefox is 51 or above.

Operating system

1. Microsoft Windows 8.1/10
2. Apple Mac OS x 10.5 or above
3. Fedora Linux Core 7 or above

Transport Layer Security (TLS)

Since old Transport Layer Security (TLS) versions may cause security risks, we highly recommend eGMS users to enable TLS version 1.2 in their browsers. Please refer to the details in **Appendix**.

Quick Guide for Completing the Electronic Application Form

(B) Access to eGMS

1. Address: <https://rfs.healthbureau.gov.hk/eGMS/>
2. Login account: If you have not registered a Principal Applicant (PA) account in the eGMS, please register on the login page of the eGMS (see below). PA will have to wait for approval from his/her Administering Institution (AI) for the creation of PA account.
3. If co-applicant is not an existing eGMS user, he/she is encouraged to register a co-applicant account from the eGMS login page in advance. Their electronic endorsement of the project will be required after submission of the application by PA.



Welcome to the electronic Grant Management System (eGMS) of the Research Fund Secretariat of the Health Bureau, HKSAR.

This is an online platform for managing the funding applications administered by the Research Fund Secretariat. The system supports electronic submission of proposals, on-line management of approved projects and dissemination of project results.

All grant applications must be submitted via this system starting from the launch of eGMS in December 2014. By setting up one single eGMS account, you can submit multiple grant applications for funding administered by the Research Office of the Health Bureau.

| | |
|---|--|
| <p>Login to eGMS</p> <p>Email: <input type="text" value="Please enter login email."/></p> <p><i>Your login email is your email address.</i></p> <p>Password: <input type="text" value="Please enter password."/></p> <p><input type="button" value="Login"/> Forgot your password?</p> <p><input type="button" value="Login"/> Forgot your login?</p> <p><input type="button" value="Login with iAM Smart"/></p> <p>More Info ></p> <p>Frequently Asked Questions</p> | <p>Account Registration (FOR APPLICANTS ONLY!)</p> <p><input type="button" value="Register for Principal Applicant Account"/></p> <p><input type="button" value="Register for Co-Applicant Account"/></p> <p>Notes to Grant Review Board (GRB) Members/ External Reviewers</p> <p>eGMS account has already been registered for GRB Members and External Reviewers. Please contact the Research Fund Secretariat (Email: egmsenquiry@healthbureau.gov.hk) if you have any questions.</p> |
|---|--|

For security reasons, with effect from 16 May 2018, the eGMS supports the following browsers: Google Chrome, Mozilla Firefox or Safari 7+ with Transport-Level-Security (TLS) protocol version 1.2. For details, please click [here](#).

Quick Guide for Completing the Electronic Application Form

(C) Complete the Web-based Online e-Form

Reminder:

Please update your eGMS profile before filling in the e-Form, as your latest personal information will be auto filled up in the e-Form (**Part 7 Project Team**).

(i) Click **Project > Application > View Application**

Application

Master List **Application Call**

(1 of 1) << 1 >> 20

| Year | Scheme | AOP | Announcement Date | AI's internal deadline | Closing Date | Actions |
|------|--------|--|-------------------|------------------------|--------------|---|
| 2023 | HMRP | Public health, human health and health services Prevention, treatment and control of infectious diseases Advanced medical research Health Promotion | 31 Oct 2023 | N/A | 29 Mar 2024 | Web-based e-Form (see Notes 1 and 2) Complete Web-based Online e-Form Download - Section 10(a)-(h) Research Proposal Template Download - Section 10(a)-(h) Health Promotion Proposal Template Download - Section 17a. (i) Excel Templates [Optional] Download - Section 17a. (ii) Excel Templates [Optional] Download - Section 18a. (i) Excel Templates [Optional] Download - Section 18a. (ii) Excel Templates [Optional] Download - Response Letter Template (For Resubmission Only) |

(ii) Click the tab **“Application Call”**

(iii) Click **“Complete Web-based Online e-Form”**

(Note: Useful templates for completing Sections 10, 17 and 18 can be downloaded here. Please refer to Pages 6-7 of this Quick Guide.)

Quick Guide for Completing the Electronic Application Form

Terms of Use

Except as otherwise provided in these Terms and Conditions, to the maximum extent permitted by applicable law, the RFS provides the System and the Services 'as is' and with all faults; and the HKSAR Government disclaims with respect to the System and the Services all warranties and conditions, whether express, implied or statutory, including without limitation any warranties or conditions of or related to accuracy, currency, merchantability, fitness for a particular or any purpose, durability, absence of defects, title, non-infringement of third party intellectual property rights, or fault-free or continuous service or operability.

Links to Third-Party Sites
The System may contain links to sites which are not under the control of the HKSAR Government. In no event shall the HKSAR Government or anyone acting on its behalf be responsible for the contents of any linked site or any link contained in a linked site or for any changes or updates to such sites. Inclusion of a link is for your convenience only and does not imply any endorsement by the HKSAR Government. You are responsible for complying with this Terms and Conditions in using any linked site. The HKSAR Government reserves the right to terminate any link or linking programme at any time.

Exclusion of Certain Damages
To the maximum extent permitted by applicable law, in no event shall the HKSAR Government or anyone acting on its behalf be liable for any direct, indirect, special, incidental or consequential damages whatsoever, including without limitation damages for personal injury, death, loss of profits, loss of confidential or other information, business interruption, loss of privacy, failure to meet any duty (including without limitation any duty of good faith or reasonable care), negligence, negligent misrepresentation, failure to warn, and any other pecuniary or other loss whatsoever, arising out of or in any way related to the System or the Services, including without limitation any use or misuse of, or inability to use, the System or the Services, or otherwise under or in connection with any provision of this Terms and Conditions, including without limitation any breach of any term or condition or a fundamental breach of this Terms and Conditions, even if the HKSAR Government or anyone acting on its behalf has been advised of the possibility of such damages.

Jurisdiction and Governing Law
This Terms and Conditions shall be governed by and construed in accordance with the laws of Hong Kong Special Administrative Region, the People's Republic of China. You agree to submit any dispute arising from or in connection with this Terms and Conditions to the exclusive jurisdiction of the courts of Hong Kong.

Notice and Limitation
In the event that you suffer any loss or damage arising from or in connection with your use, misuse or inability to use this System or the Services, you shall not commence any claim or proceeding, arising from or in connection with the System or the Services, unless and until you have delivered notice of such loss and damage and provided the RFS with sixty (60) days to correct such situation. In any event, you shall not bring any claim against the HKSAR Government more than six (6) months after the purported cause of action has arisen. The RFS's address for legal notices is 9/F, Rumsey Street Multi-storey Carpark Building, 2 Rumsey Street, Sheung Wan Hong Kong.

Severability
The provisions of this Terms and Conditions are severable, and should any provision hereof be void, voidable or unenforceable under any applicable law, such void, voidable or unenforceable provision shall not affect or invalidate any other provisions of this Terms and Conditions, which shall continue to govern as though the void, voidable or unenforceable provision were not a part hereof.

Suspension and Termination
The HKSAR Government or anyone acting on its behalf reserves the right to suspend and/or terminate your use of the System, and your password, PIN and/or username at any time without notice to you.

You need to scroll through all the contents in the Terms of Use before you are able to click the check box below.

- I have read and agreed with the above Terms of Use.
- I understand that I have to read the Explanatory Notes and Guidance Notes for Research Grant Application before completing the application form.
- I understand that applications that are outside the funding scope, incomplete, inconsistent with the submission requirements, or insufficiently detailed will not be processed and may result in administrative withdrawal.
- I understand that I have to use the correct proposal template for research/health promotion project under Section 10, otherwise my application will not be processed.
- I understand that I have to state clearly the pre-set criteria for process and outcome evaluation based on the RE-AIM framework for health promotion project.
- I understand that agreement for newly approved grant will not be issued if I have not submitted the outstanding / overdue report(s) / certified financial statement(s) and audited account(s) / outcome evaluation questionnaire(s) for my other grants supported by the HMRF.

(iv) Read the Terms of Use, tick the boxes and click “Continue”

(v) Click the button to go to relevant Section directly

1
of 18

| | | | |
|-------------------------------|---|---------------------------------|-------------------------------------|
| Basic Information (1 to 5) | Potential Application (6) | Project Team (7) | Proposed Field, Keyword (8 to 9) |
| Project Proposal (10) | Project Duration, Timetable of work (11 to 12) | Budget Plan (13 to 14) | Ethics Approval (15) |
| CV (16) | Related Proposal and Track Records (17 to 18) | Nomination of Reviewers (19) | Declaration (20) |

(Attention: The eGMS will be logged out automatically if the screen has been idling for 20 minutes. There is no auto-save function. Please be reminded to use the “Save” function to save your work regularly.)

Quick Guide for Completing the Electronic Application Form

(vi) Click “Save” to save the e-Form and “Yes” for confirmation.

The screenshot shows the top navigation area of the e-Form. At the top left, there are two buttons: 'Save' (circled in red) and 'Submit'. Below these buttons, on the left, is a progress indicator showing '1 of 18' and a 'Next' button. The main area contains a grid of 13 grey buttons representing different sections of the form:

| | | | |
|-------------------------------|---|---------------------------------|-------------------------------------|
| Basic Information (1 to 5) | Potential Application (6) | Project Team (7) | Proposed Field, Keyword (8 to 9) |
| Project Proposal (10) | Project Duration, Timetable of work (11 to 12) | Budget Plan (13 to 14) | Ethics Approval (15) |
| CV (16) | Related Proposal and Track Records (17 to 18) | Nomination of Reviewers (19) | Declaration (20) |

Below the grid, a 'Confirm' dialog box is displayed. It has a blue header with the text 'Confirm'. The main text reads 'Are you sure to Save ?' with a warning icon. At the bottom, there are two buttons: 'Yes' (circled in red) and 'No'.

(vii) An acknowledgment message will be displayed on the top showing the e-Form has been saved with a temporary Ref. No.



Quick Guide for Completing the Electronic Application Form

(D) Supplementary Information for Completing Sections 10, 17 and 18 of the eForm

1. Go to Application > Application Call page

Application

| Year | Scheme | AOP | Announcement Date | AI's internal deadline | Closing Date | Actions |
|------|--------|--|-------------------|------------------------|--------------|---|
| 2023 | HMRF | Public health, human health and health services Prevention, treatment and control of infectious diseases Advanced medical research Health Promotion | 31 Oct 2023 | N/A | 29 Mar 2024 | Web-based e-Form (see Notes 1 and 2) Complete Web-based Online e-Form Download - Section 10(a)-(h) Research Proposal Template Download - Section 10(a)-(h) Health Promotion Proposal Template Download - Section 17a (i) Excel Templates [Optional] Download - Section 17a (ii) Excel Templates [Optional] Download - Section 18a (i) Excel Templates [Optional] Download - Section 18a (ii) Excel Templates [Optional] Download - Response Letter Template (For Resubmission Only) |

For Section 10 (a) – (h), after you have completed the “Research Proposal” or “Health Promotion” template (in MS Word), please convert it into a PDF file and then click “Browse”. Select the PDF file and upload it. (The file size should not exceed 600KB.)

10. PROJECT PROPOSAL

Please attach (a) – (h) of the proposal (in PDF format only and the maximum file size is 600KB):

I confirm that I have used the correct proposal template for research/health promotion project under Section 10, and understand that my application will not be processed if incorrect proposal template has been used.

Word count for S

| 名稱 | 修改日期 | 類型 |
|--------------------------------------|-----------------|-------------------|
| HMRF_Proposed_Research_Project_20... | 8/11/2023 18:49 | Adobe Acrobat ... |

檔案名稱(N): HMRF_Proposed_Research_Project_2023.pdf 開啟(O) 取消

Uploaded file name : [HMRF_Proposed_Research_Project_2023.pdf](#)

Quick Guide for Completing the Electronic Application Form

For Sections 17 to 18, after completing the excel file of the relevant records from you and project team members, please click “Browse”, select the PDF file and upload it. (The file size should not exceed 1MB.)

An example in Section 17a(i) is stated below -

17. SIMILAR OR RELATED PROPOSALS
Attention: Failure to make declaration may lead to application not eligible for further processing and shall be subject to penalty as determined by the Research Council.

THIS APPLICATION

17a. (i) Have any of the applicants listed in Section 7 submitted this or a similar proposal to the HMRF or other funding agencies in the past 3 years? YES NO

Attention: Include all similar proposals funded or rejected by HMRF or other funding agencies in the past three years from the closing deadline. Proposals rejected or not supported by HMRF or other funding agencies (local or overseas) must be submitted as new applications with extensive changes or improvements. Attach a copy of each of the previously submitted similar applications, the reviewers' comments (if any), and point-by-point response to the reviewers' comments.

Upload

If yes, please provide the following details:-

| No. | Project Title | Name of Applicant(s) |
|-----|---------------|----------------------|
| 1 | | |

Attach file(s)

Browse Delete

Upload Cancel

| 名稱 | 修改日期 | 類型 |
|--------------------------------|-----------------|-------------------|
| submitted_similar_proposal.pdf | 8/11/2023 18:49 | Adobe Acrobat ... |

檔案名稱(N): submitted_similar_proposal.pdf All Files (*.*)

開啟(O) 取消

Quick Guide for Completing the Electronic Application Form

(E) Need Help?

1. If some fields are not completed according to the format, error message box will pop up when you click the “Submit” button in the application form. Please edit the application form again and re-submit.
2. For enquiry, please contact the Research Fund Secretariat by email (egmsenquiry@healthbureau.gov.hk), or by phone at 3427 3344 during office hours.

Quick Guide for Completing the Electronic Application Form


Appendix

1. Google Chrome

(a) We recommend eGMS user to use version 57 or above. If you are using Google Chrome version 22 or above, TLS 1.1 is automatically supported. TLS 1.1 and 1.2 are automatically enabled from version 29 or above.


(b) To find out which version of google chrome you are using -

- i. Open your Chrome browser.
- ii. Click the “More” icon at the right corner of the address bar.



iii. At the bottom of the menu, click “Help”, then click “About Google Chrome”

iv. The version of Google Chrome will be shown



(c) To update Google Chrome:

- i. Chrome will check for any updates and immediately download them when you open the About Google Chrome page



- ii. Close your browser and restart Chrome to complete the updates

Quick Guide for Completing the Electronic Application Form

Appendix

2. Mozilla Firefox

(a) Set the TLS version of the browser

- i. Open Firefox browser
- ii. In the address bar, type “about:config” and press “Enter”



- iii. In the Search field, enter “tls”. Find and double-click the entry for “security.tls.version.max”



- iv. Set the integer value to 2 to force a minimum protocol of TLS 1.1
- v. Set the integer value to 4 to force a maximum protocol of TLS 1.3


| 偏好設定名稱 | 狀態 | 類型 | 值 |
|---|-----|------------------|-------|
| devtools.remote.tls-handshake-timeout | 預設值 | 整數 | 10000 |
| gl.use-tls-is-current | 預設值 | 整數 | 0 |
| network.http.spdy.enforce-tls-profile | 預設值 | 布林 (Boolean) 值 | true |
| network.http.tls-handshake-timeout | 預設值 | 整數 | 30 |
| network.proxy.proxy_over_tls | 預設值 | 布林 (Boolean) 值 | true |
| security.tls.enable_Ortt_data | 預設值 | 布林 (Boolean) 值 | true |
| security.tls.enable_post_handshake_auth | 預設值 | 布林 (Boolean) 值 | false |
| security.tls.hello_downgrade_check | 預設值 | 布林 (Boolean) 值 | false |
| security.tls.insecure_fallback_hosts | 預設值 | 字串 | |
| security.tls.version.fallback-limit | 預設值 | 整數 | 4 |
| security.tls.version.max | 預設值 | 整數 | 4 |
| security.tls.version.min | 已修改 | 整數 | 2 |

- vi. Click “OK”
- vii. Close your Firefox browser and restart your Firefox browser
- viii. Recommended version 51 or above

Quick Guide for Completing the Electronic Application Form

Appendix

- (b) To find out which version of Firefox browser you are using:
- i. Open your Firefox browser
 - ii. At the top of your Firefox browser, to the right of the address bar, click the “Menu” icon



- iii. At the bottom of the menu, click “Help”, then “About Firefox”
- iv. The version of Firefox browser will be shown



(Note: Updated version will be downloaded automatically)



- v. Close your browser and restart Firefox browser to complete the update

3. Safari

There are no options for enabling SSL protocols. If you are using Safari version 7 or above, TLS 1.2 is automatically enabled.

Classification of Areas of Expertise (Research Field) (Version 3.0)

Adapted and modified (with permission) from the Australian Bureau of Statistics:

Australian Bureau of Statistics (ABS) and Statistics New Zealand (Statistics NZ). *Australia and New Zealand Standard Research Classification (ANZSRC) 2008*, cat. no. 1297.0, ABS, Canberra, 31 Mar 2008, <http://www.abs.gov.au/2008>.

This work is based on Statistics New Zealand's data which are licensed by Statistics New Zealand for re-use under the Creative Commons Attribution 3.0 New Zealand licence

| Group No. | Field No. |
|--|---|
| A01 Cardiorespiratory medicine and haematology | A01-01 Vascular medicine and surgery (<i>incl. cardiology</i>) |
| | A01-02 Haematology (<i>incl. blood transfusion</i>) |
| | A01-03 Respiratory medicine |
| | A01-99 Cardiorespiratory medicine and haematology not elsewhere classified Please specify. |
| A02 Clinical sciences | A02-01 Anaesthesiology |
| | A02-02 Dermatology |
| | A02-03 Emergency medicine |
| | A02-04 Endocrinology (<i>incl. diabetes mellitus, obesity-related metabolic disorders</i>) |
| | A02-05 Gastroenterology and hepatology |
| | A02-06 Geriatrics and gerontology |
| | A02-07 Infectious diseases (<i>incl. prevention, control, treatment and management of patients</i>) (<i>Please also refer to A04 for Medical microbiology</i>) |
| | A02-08 Intensive care |
| | A02-09 Nephrology and urology |
| | A02-10 Nuclear medicine |
| | A02-11 Orthopaedics |
| | A02-12 Otorhinolaryngology |
| | A02-13 Pathology (<i>excl. oral pathology</i>) |
| | A02-14 Physiotherapy |
| | A02-15 Podiatry |
| | A02-16 Radiology and organ imaging |
| | A02-17 Rehabilitation and therapy (<i>incl. occupational therapy but excl. physiotherapy</i>) |
| | A02-18 Rheumatology and arthritis |
| | A02-19 Surgery |
| | A02-20 Venereology |
| | A02-21 Palliative medicine and care |
| | A02-22 Sleep medicine |
| A02-99 Clinical sciences not elsewhere classified Please specify. | |
| A03 Traditional Chinese Medicine | A03-01 Traditional Chinese Medicine (<i>natural products, incl. herbs</i>) |
| | A03-02 Acupuncture (<i>incl. electroacupuncture, auriculotherapy</i>) |
| | A03-03 Mind-body therapies (<i>incl. Taichi, Qigong, Yoga, mindfulness and relaxation training</i>) |
| | A03-04 Manipulative and body-based practices (<i>incl. guasha, tuina, etc</i>) |
| | A03-05 Integration of Traditional Chinese Medicine with conventional therapy |
| A03-99 Traditional Chinese Medicine not elsewhere classified Please specify. | |
| A04 Medical microbiology (microbiology related to human medicine and health, laboratory diagnosis) | A04-01 Medical bacteriology (<i>incl. antibiotic resistance</i>) |
| | A04-02 Medical infection agents (<i>incl. prions</i>) |
| | A04-03 Medical parasitology |
| | A04-04 Medical virology |
| | A04-05 Medical mycology |
| | A04-06 Infection control |
| A04-99 Medical microbiology not elsewhere classified Please specify. | |
| A05 Mental health and behavioural disorders (<i>incl. dementia, Alzheimer's disease, delirium, addictive behaviour, schizophrenia, psychosis, depression, anxiety, sleep disorders, attention deficit hyperactivity disorder (ADHD), autism, post-traumatic stress disorders, violence</i>) | A05-01 Organic, including symptomatic, mental disorders (<i>incl. dementia, Alzheimer's disease, delirium</i>) |
| | A05-02 Mental and behavioural disorders due to psychoactive substance use (<i>incl. addiction, smoking, drinking alcohol</i>) |
| | A05-03 Schizophrenia, schizotypal and delusional disorders (<i>incl. psychosis</i>) |
| | A05-04 Mood [affective] disorders (<i>incl. mania, depression</i>) |
| | A05-05 Neurotic, stress-related and somatoform disorders (<i>incl. stress, anxiety, somatoform pain, post-traumatic stress disorders</i>) |
| | A05-06 Behavioural syndromes associated with physiological disturbances and physical factors (<i>incl. eating disorders, nonorganic sleep disorders; non-disease-based sexual dysfunction, abuse of non-dependence-producing substances</i>) |
| | A05-07 Disorders of adult personality and behaviour (<i>incl. habit and impulse disorders, self-harm, gender identity disorders, violence</i>) |
| | A05-08 Mental retardation |
| | A05-09 Disorders of psychological development (<i>incl. specific development disorders of speech and language, reading and spelling disorders, autism spectrum disorders, overactive disorder associated with mental retardation and stereotyped movements</i>) |
| | A05-10 Behavioural and emotional disorders with childhood and adolescence onset (<i>incl. hyperkinetic disorder, attention-deficit hyperactivity disorder (ADHD), conduct disorders (e.g. school violence), Tic disorders</i>) |
| A05-99 Mental health not elsewhere classified Please specify. | |
| A06 Neurosciences (<i>incl. Parkinson's disease, epilepsy, multiple sclerosis, stroke</i>) | A06-01 Autonomic nervous system |
| | A06-02 Cellular nervous system (nervous system at the cellular and molecular levels) |
| | A06-03 Central nervous system (<i>incl. Parkinson's disease, epilepsy, multiple sclerosis, stroke</i>) |
| | A06-04 Neuromuscular system |
| | A06-05 Peripheral nervous system |
| | A06-06 Sensory systems |
| A06-99 Neurosciences not elsewhere classified Please specify. | |
| A07 Psychology | A07-01 Health psychology |
| | A07-02 Clinical and counselling psychology |
| | A07-03 Risk behaviour |
| | A07-04 Behavioural decision-making (<i>incl. decision science and behavioural economics</i>) |
| | A07-99 Psychology not elsewhere classified Please specify. |
| A08 Cognitive sciences | A08-01 Linguistic processes (<i>incl. speech production and comprehension</i>) |
| | A08-02 Neurocognitive patterns and neural networks |
| | A08-99 Cognitive sciences not elsewhere classified Please specify. |

| Group No. | Field No. |
|--|---|
| A09 Dentistry | A09-01 Dental materials and equipment |
| | A09-02 Dental therapeutics, pharmacology and toxicology |
| | A09-03 Endodontics |
| | A09-04 Oral and maxillofacial surgery |
| | A09-05 Oral medicine and pathology |
| | A09-06 Orthodontics and dentofacial orthopaedics |
| | A09-07 Paedodontics |
| | A09-08 Periodontics |
| | A09-09 Special needs dentistry |
| | A09-10 Dental public health |
| | A09-11 Oral biosciences (<i>incl. oral microbiology</i>) |
| | A09-99 Dentistry not elsewhere classified Please specify. |
| A10 Nursing | A10-01 Aged care nursing |
| | A10-02 Clinical nursing: primary (preventive), secondary (acute care), tertiary (rehabilitative) |
| | A10-03 Mental health nursing |
| | A10-04 Midwifery |
| | A10-99 Nursing not elsewhere classified Please specify. |
| A11 Nutrition and dietetics | A11-01 Clinical and sports nutrition |
| | A11-02 Dietetics and nutrigenomics |
| | A11-03 Nutritional physiology |
| | A11-04 Nutrition |
| | A11-99 Nutrition and dietetics not elsewhere classified Please specify. |
| A12 Oncology and carcinogenesis | A12-01 Cancer biology |
| | A12-02 Cancer diagnosis and prognosis (<i>incl. cancer markers</i>) |
| | A12-03 Cancer genetics, genomics and epigenetics |
| | A12-04 Cancer therapy (<i>excl. chemotherapy and radiation therapy</i>) |
| | A12-05 Chemotherapy |
| | A12-06 Haematological tumours |
| | A12-07 Molecular targets |
| | A12-08 Radiation therapy |
| | A12-09 Solid tumours |
| | A12-10 Psychosocial oncology |
| | A12-99 Oncology and carcinogenesis not elsewhere classified Please specify. |
| A13 Ophthalmology and optometry | A13-01 Ophthalmology |
| | A13-02 Optical technology |
| | A13-03 Vision science |
| | A13-99 Ophthalmology and optometry not elsewhere classified Please specify. |
| A14 Paediatrics and reproductive medicine | A14-01 Foetal development and medicine |
| | A14-02 Obstetrics and gynaecology |
| | A14-03 Paediatrics (<i>incl. neonatology</i>) |
| | A14-04 Reproduction (<i>incl. infertility</i>) |
| | A14-99 Paediatrics and reproductive medicine not elsewhere classified Please specify. |
| A15 Pharmacology and pharmaceutical sciences | A15-01 Basic pharmacology (<i>non-human laboratory experiments incl. animal, organ, tissue</i>) |
| | A15-02 Clinical pharmacology and therapeutics (<i>incl. pharmacokinetics, pharmacodynamics, pharmacoepidemiology</i>) |
| | A15-03 Clinical pharmacy and pharmacy practice |
| | A15-04 Pharmaceutical sciences (formulation and drug delivery research) |
| | A15-05 Pharmacogenomics |
| | A15-06 Toxicology (<i>incl. clinical toxicology</i>) |
| | A15-99 Pharmacology and pharmaceutical sciences not elsewhere classified Please specify. |
| A16 Public health and health sciences | A16-01 Aged health care |
| | A16-02 Care for disabled |
| | A16-03 Community child health |
| | A16-04 Environmental and occupational health and safety |
| | A16-05 Epidemiology |
| | A16-06 Family care |
| | A16-07 Health and community services (<i>incl. services provided at the interface between primary and secondary care, health and social services</i>) |
| | A16-08 Health care administration (<i>incl. services provided at ONE specific sector at primary or secondary care</i>) |
| | A16-09 Health counselling |
| | A16-10 Health information systems (<i>incl. surveillance</i>) |
| | A16-11 Health promotion (<i>incl. physical activity</i>) |
| | A16-12 Preventive medicine |
| | A16-13 Primary health care |
| | A16-14 Quality of life research |
| | A16-15 Complex interventions evaluation |
| | A16-16 Food safety |
| | A16-17 Public health genomics and screening |
| | A16-18 Adolescent health |
| | A16-19 Vaccination programme |
| A16-99 Public health and health services not elsewhere classified Please specify. | |
| A17 Immunology | A17-01 Allergy |
| | A17-02 Applied immunology (<i>incl. vaccine science and development, antibody engineering, xenotransplantation and T-cell</i>) |
| | A17-03 Autoimmunity |
| | A17-04 Cellular immunology |
| | A17-05 Humoral immunology and immunochemistry |
| | A17-06 Immunogenetics (<i>incl. genetic immunology</i>) |
| | A17-07 Innate immunity |
| | A17-08 Transplantation immunology |
| | A17-09 Tumour immunology |
| | A17-99 Immunology not elsewhere classified Please specify. |

| Group No. | Field No. |
|---|--|
| A18 Human movement and sports science | A18-01 Movement control and biomechanics |
| | A18-02 Exercise physiology |
| | A18-03 Sports medicine |
| | A18-04 Sport and exercise psychology |
| | A18-99 Human movement and sports science not elsewhere classified Please specify. |
| A19 Mathematics and Statistics in Health | A19-01 Biostatistics |
| | A19-02 Meta-analysis |
| | A19-03 Clinical trial research methodology |
| | A19-04 Instrument development (incl. self-reported outcomes, psychometric analysis) |
| | A19-05 Mathematical modelling |
| A19-99 Statistics not elsewhere classified Please specify. | |
| A20 Biochemistry and cell biology | A20-01 Analytical biochemistry |
| | A20-02 Bioinformatics |
| | A20-03 Metabolomics, proteomics and intermolecular interactions |
| | A20-04 Cellular processes, signal transduction and mechanisms |
| | A20-05 Stem cell |
| | A20-06 Genomics, Genetics and epigenetics (excl. cancer genetics) |
| | A20-07 Protein chemistry (incl. protein functions and dynamics) |
| | A20-08 Structural biology (incl. proteins, nucleic acids) |
| | A20-09 RNA biology (incl. non-coding RNA) |
| | A20-99 Biochemistry and cell biology not elsewhere classified Please specify. |
| A21 Analytical chemistry | A21-01 Analytical spectrometry |
| | A21-02 Electroanalytical chemistry |
| | A21-03 Immunological and bioassay methods |
| | A21-04 Instrumental methods (excl. immunological and bioassay methods) |
| | A21-05 Quality assurance, chemometrics, traceability and metrological chemistry |
| | A21-06 Sensor technology (chemical aspects) |
| | A21-99 Analytical chemistry not elsewhere classified Please specify. |
| A22 Macromolecular and material chemistry | A22-01 Chemical characterisation of materials |
| | A22-02 Physical chemistry of materials |
| | A22-03 Synthesis of materials |
| | A22-99 Macromolecular and material chemistry not elsewhere classified Please specify. |
| A23 Medicinal and biomolecular chemistry | A23-01 Biomolecular modelling and design (incl. drug design and development) |
| | A23-99 Medicinal and biomolecular chemistry not elsewhere classified Please specify. |
| A24 Organic chemistry | A24-01 Natural product chemistry |
| | A24-99 Organic chemistry not elsewhere classified Please specify. |
| A25 Environmental science and management | A25-01 Environmental management |
| | A25-02 Environmental monitoring |
| | A25-03 Environmental science |
| | A25-99 Environmental science and management not elsewhere classified Please specify. |
| A26 Biomedical engineering | A26-01 Biomaterials |
| | A26-02 Biomechanical engineering |
| | A26-03 Biomedical instrumentation (incl. surgical instrumentation) |
| | A26-04 Medical devices (incl. implants, prosthetics) |
| | A26-05 Rehabilitation engineering |
| A26-99 Biomedical engineering not elsewhere classified Please specify. | |
| A27 Medical biotechnology | A27-01 Gene and molecular therapy |
| | A27-02 Medical biotechnology diagnostics (incl. biosensors) |
| | A27-03 Medical molecular engineering of nucleic acids and proteins |
| | A27-04 Regenerative medicine (incl. stem cells and tissue engineering) |
| A27-99 Medical biotechnology not elsewhere classified Please specify. | |
| A28 Nanotechnology | A28-01 Nanomaterials |
| | A28-02 Nanomedicine |
| | A28-03 Nanotoxicology, health and safety |
| | A28-99 Nanotechnology not elsewhere classified Please specify. |
| A29 Specialist studies in education | A29-01 Learning sciences |
| | A29-02 Special education and disability |
| | A29-99 Specialist studies in education not elsewhere classified Please specify. |
| A30 Applied economics | A30-01 Health economics |
| | A30-99 Applied economics not elsewhere classified Please specify. |
| A31 Demography | A31-01 Family and household studies |
| | A31-02 Fertility |
| | A31-03 Migration |
| | A31-04 Mortality |
| | A31-05 Population trends and policies |
| A31-99 Demography not elsewhere classified Please specify. | |
| A32 Policy and administration | A32-01 Environment policy |
| | A32-02 Health policy |
| | A32-99 Policy and administration not elsewhere classified Please specify. |

| Group No. | Field No. |
|--------------------|---|
| A33 Applied ethics | A33-01 Medical ethics |
| | A33-99 Applied ethics not elsewhere classified Please specify. |
| A99 Others | A99-99 Health and medical research not elsewhere specified Please specify. |